SAN ANTONIO – In a global study involving more than 5,000 women, risk-reducing surgeries significantly improved survival and ...

A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission ...

Researchers founded Rarity PBC as a public benefit corporation that will license the IP and develop operations to potentially ...

Due to unfavorable pharmacokinetics and the development costs of BRAF V600E and KRAS G12C mutated cancers, the firm will not advance the STARMAP trial.

The variant, present in the NFKB1 gene and common in the Aymara community, could help guide treatment decisions, researchers ...

Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on ...

Editas, which was unable to identify a development or licensing partner for reni-cel, is focusing its resources on its in vivo pipeline.

SAN DIEGO – Gilead Sciences and Arcellx's autologous B-cell maturation antigen (BCMA)-directed CAR T-cell therapy ...

Researchers presented data from trials of HER2-targeted therapies from Jiangsu Hengrui Medicine, Jazz Pharma, Roche, and RemeGen.

The new HER2-low category is exposing the limitations of IHC testing, challenging pathologists, and has oncologists ...

In particular, patients who had fewer than 10 annual vaso-occlusive events before the gene therapy were more likely to have ...

Lymphoma patients better tolerated the CAR T-cell therapy manufactured on site at the Sheba Medical Center than they did the ...